Table 1.
Baseline characteristics of patients in the Australian IPF Registry
| Variable | n | overall | Mild (FVC ≥ 80%) | Moderate-Severe (FVC < 80%) | Pa | Min | Max |
|---|---|---|---|---|---|---|---|
| 216 | 200 | ||||||
| Age, years | 416 | 70.4 (8.6) | 71.6 (7.9) | 69.0 (9.1) | 0.003 | 31.5 | 89.9 |
| Male, n (%) | 416 | 290 (69.7%) | 125 (57.9%) | 165 (82.5%) | <0.001 | ||
| Ever smoker, n (%) | 416 | 308 (74.0%) | 160 (74%) | 148 (74%) | 0.986 | ||
| BMI, kg/m2 | 412 | 28.8 (4.8) | 28.9 (5.0) | 28.6 (4.6) | 0.565 | 15.8 | 46.4 |
| FVC, L | 416 | 2.6 (0.8) | 2.96 (0.79) | 2.30 (0.54) | <0.001 | 0.9 | 4.8 |
| FVC, % pred | 416 | 81.7 (21.2) | 97.3 (16.6) | 64.9 (9.8) | <0.001 | 40.9 | 219.5 |
| FEV1/FVC ratio% | 416 | 82.2 (8.4) | 80.1 (8.6) | 84.4 (7.5) | <0.001 | 27.0 | 135.0 |
| DLco, % pred | 416 | 48.5 (16.8) | 54.6 (17.4) | 41.8 (13.2) | <0.001 | 9.4% | 143.7% |
| CPI | 416 | 45.1 (14.1) | 37.5 (13.2) | 53.3 (9.7) | <0.001 | 54.2 | 74.5 |
| GAP stage | 416 | <0.001 | |||||
| GAP stage 1 | 192 (46.2%) | 152 (70.4%) | 40 (20.0%) | ||||
| GAP stage 2 | 186 (44.7%) | 64 (29.6%) | 122 (61.0%) | ||||
| GAP stage 3 | 38 (9.1%) | 0 (0%) | 38 (19.0%) | ||||
| 6MWT distance, m | 164 | 431.0 (119) | 433 (115) | 430 (122) | 0.894 | 48.0 | 706.0 |
| Initial SpO2, % | 163 | 95.5 (3.19) | 95.8 (3.4) | 95.4 (3.1) | 0.482 | 83.0 | 100.0 |
| End SpO2, % | 160 | 86.2 (7.2) | 89.0 (7.0) | 84.4 (6.8) | <0.001 | 58.0 | 99.0 |
| Nadir SpO2, % | 153 | 85.3 (7.1) | 87.9 (7.3) | 83.6(6.5) | <0.001 | 58.0 | 99.0 |
| SGRQ | 383 | 43.0 (19.7) | 38.7 (19.0) | 47.6 (44.8) | <0.001 | 0.0 | 96.6 |
| UCSD SOBQ | 243 | 40.8 (29.3) | 33.7(27.1) | 48.6 (29.6) | <0.001 | 0.0 | 119.0 |
| Cough severity | 347 | 39.5 (23.5) | 36.9 (22.9) | 42.3(23.9) | 0.034 | 0.0 | 100.0 |
| Anti-fibrotic therapy | 416 | 102 (24.5%) | 52 (24.1%) | 50 (25.0%) | 0.826 |
acomparison between mild and severe physiological impairment